{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:23:48Z","timestamp":1791044628152,"version":"4.1.0"},"reference-count":43,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,4,7]],"date-time":"2005-04-07T00:00:00Z","timestamp":1112832000000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2005,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Fibromyalgia syndrome (FMS) is characterized by widespread musculoskeletal pain and lowered pain threshold. Other prominent symptoms include disordered sleep and fatigue. FMS affects an estimated 2% of the population, predominantly women. This trial was designed to evaluate the efficacy and safety of pregabalin, a novel \u03b1<jats:sub>2<\/jats:sub>\u2010\u03b4 ligand, for treatment of symptoms associated with FMS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This multicenter, double\u2010blind, 8\u2010week, randomized clinical trial compared the effects of placebo with those of 150, 300, and 450 mg\/day pregabalin on pain, sleep, fatigue, and health\u2010related quality of life in 529 patients with FMS. The primary outcome variable was the comparison of end point mean pain scores, derived from daily diary ratings of pain intensity, between each of the pregabalin treatment groups and the placebo group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Pregabalin at 450 mg\/day significantly reduced the average severity of pain in the primary analysis compared with placebo (\u22120.93 on a 0\u201310 scale) (<jats:italic>P<\/jats:italic> \u2264 0.001), and significantly more patients in this group had \u226550% improvement in pain at the end point (29%, versus 13% in the placebo group; <jats:italic>P<\/jats:italic> = 0.003). Pregabalin at 300 and 450 mg\/day was associated with significant improvements in sleep quality, fatigue, and global measures of change. Pregabalin at 450 mg\/day improved several domains of health\u2010related quality of life. Dizziness and somnolence were the most frequent adverse events. Rates of discontinuation due to adverse events were similar across all 4 treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Pregabalin at 450 mg\/day was efficacious for the treatment of FMS, reducing symptoms of pain, disturbed sleep, and fatigue compared with placebo. Pregabalin was well tolerated and improved global measures and health\u2010related quality of life.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.20983","type":"journal-article","created":{"date-parts":[[2005,4,7]],"date-time":"2005-04-07T15:22:34Z","timestamp":1112887354000},"page":"1264-1273","source":"Crossref","is-referenced-by-count":517,"title":["Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double\u2010blind, placebo\u2010controlled trial"],"prefix":"10.1002","volume":"52","author":[{"given":"Leslie J.","family":"Crofford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Rowbotham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Jon","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Dworkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann E.","family":"Corbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James P.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda K.","family":"LaMoreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Pregabalin 1008\u2010105 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,4,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380104"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330203"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10217"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1521-6942(03)00035-4"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-199305020-00013"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(99)71272-7"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-001-0011-8"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.4.343"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(01)00011-4"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.10.5768"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.59.5.1243"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.62.3.485"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-4388(03)00066-7"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M313450200"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(01)00172-1"},{"key":"e_1_2_6_17_2","first-page":"1086","article-title":"Stimulus\u2010dependent modulation of [3H]\u2010norepinephrine release from rat neocortical slices by gabapentin and pregabalin","volume":"295","author":"Dooley DJ","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(00)00769-2"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00316-5"},{"key":"e_1_2_6_20_2","first-page":"159","article-title":"Meeting report: the biology and pharmacology of calcium channel proteins","volume":"10","author":"Taylor CP","year":"2004","journal-title":"CNS Drug Rev"},{"key":"e_1_2_6_21_2","first-page":"829","volume-title":"Antiepileptic drugs","author":"Taylor CP","year":"1995"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1059-1311(02)00295-9"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003251119"},{"key":"e_1_2_6_24_2","first-page":"P18","article-title":"Metabolic disposition of pregabalin in healthy volunteers","volume":"69","author":"Corrigan BW","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000145767.36287.A1"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.05.001"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000055433.55136.55"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(87)91074-8"},{"key":"e_1_2_6_29_2","first-page":"232","volume-title":"Measuring functioning and well\u2010being","author":"Hays RD","year":"1992"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006199-199303000-00006"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"e_1_2_6_33_2","first-page":"377","article-title":"A standardized manual tender point survey. I. Development and determination of a threshold point for the identification of positive tender points in fibromyalgia syndrome","volume":"24","author":"Okifuji A","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_6_34_2","volume-title":"Coding symbols for a thesaurus of adverse reaction terms (COSTART)","year":"1996"},{"key":"e_1_2_6_35_2","volume-title":"Statistical methodology in the pharmaceutical sciences","author":"Berry D","year":"1990"},{"key":"e_1_2_6_36_2","volume-title":"SAS\/STAT users guide. Version 6","author":"SAS Institute, Inc.","year":"1989"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/75.4.800"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(01)00349-9"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(03)00116-5"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(05)70273-8"},{"key":"e_1_2_6_41_2","first-page":"1407","article-title":"The prevalence and meaning of fatigue in rheumatic disease","volume":"23","author":"Wolfe F","year":"1996","journal-title":"J Rheumatol"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-857X(21)00029-6"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000084032.22282.ff"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.3.533"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.20983","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.20983","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T20:42:15Z","timestamp":1697056935000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.20983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["10.1002\/art.20983"],"URL":"https:\/\/doi.org\/10.1002\/art.20983","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}